Aromatherapy Inhalation in Psychiatric Nurses

February 5, 2025 updated by: SERDAR TÜRKYILMAZ

The Effect of Aromatherapy Inhalation on the Therapeutic Relationship and Work Stress Levels of Psychiatric Nurses

In this study will be conducted with a total of 66 psychiatric nurses who meet the inclusion and exclusion criteria and are working at Ankara Etlik City Hospital Psychiatry Clinic between January 1, 2025 and March 31, 2025.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In this study, aromatherapy inhalation will be applied to psychiatric nurses in the experimental group. Aromatherapy inhalation using 2% diluted lavender essential oil will be applied to 33 psychiatric nurses in the experimental group, 30 minutes before starting work, every other day during a week. The "General Job Stress Scale (GJSS)" and "Therapeutic Relationship Evaluation Scale-Nurse Form (TRES-NF)" inventories will be filled out by 33 psychiatric nurses in the experimental group before and after aromatherapy inhalation, and by 33 psychiatric nurses in the control group simultaneously with the psychiatric nurses in the experimental group.

Study Type

Interventional

Enrollment (Actual)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Yenimahalle
      • Ankara, Yenimahalle, Turkey
        • Ankara Etlik City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Written permission was obtained before participating in the study
  • Having worked in the psychiatry departments of the relevant institution for at least 1 year
  • Working in the psychiatry departments of the relevant institution during the study dates
  • Not sensitive to the odor of lavender essential oil

Exclusion Criteria:

  • Previous experience with aromatherapy
  • Sensitivity and allergy to lavender essential oil
  • Willingly leaving the study while the study was ongoing
  • Leaving the job during the study period
  • General condition changes during the study period (developing allergies, getting sick, taking annual leave, taking leave with a health report)
  • Becoming a service responsible nurse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental group
In this study, aromatherapy inhalation will be applied to psychiatric nurses in the experimental group. Aromatherapy inhalation using 2% diluted lavender essential oil will be applied to 33 psychiatric nurses in the experimental group, 30 minutes before starting work, every other day during a week. The "General Job Stress Scale (GJSS)" and "Therapeutic Relationship Evaluation Scale-Nurse Form (TRES-NF)" inventories will be filled out by 33 psychiatric nurses in the experimental group before and after aromatherapy inhalation, and by 33 psychiatric nurses in the control group simultaneously with the psychiatric nurses in the experimental group.
Other: Aromatherapy Inhalation in Psychiatric Nurses
Aromatherapy inhalation using 2% diluted lavender essential oil will be applied to 33 psychiatric nurses in the experimental group, 30 minutes before starting work, every other day during a week. The lavender essential oil to be used in the study will be dropped 3 drops onto a cotton handkerchief cut into a disc shape and fixed to the clothes of the psychiatric nurses, 20 cm away from their noses, and they will be asked to inhale it for 30 minutes.
No Intervention: Control group
There will be no training or intervention. No intervention will be made to the 33 psychiatric nurses in the control group. The psychiatric nurses in the control group will be asked to fill out the "General Job Stress Scale (GJSS)" and "Therapeutic Relationship Evaluation Scale-Nurse Form (TRES-NF)" inventories simultaneously with the 33 psychiatric nurses in the experimental group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
General Job Stress Scale (GJSS)
Time Frame: Change from before implementation, after practice is completed (1th week)
The Turkish validity and reliability of the scale developed by De Bruin (2006) to measure the general job stress of employees was provided by Teleş (2020). The scale has a one-dimensional structure that addresses the emotional, cognitive, motivational and social consequences of job stress. The scale, which has no sub-dimensions and consists of a five-point Likert-type and nine items, is stated as "1=Never, 2=Rarely, 3=Sometimes, 4=Mostly, 5=Always". The total score to be obtained from the scale is a concrete expression of job stress and a high score to be obtained from the scale indicates that high job stress is experienced. As a result of the validity and reliability study conducted by Teleş (2020), the Cronbach alpha coefficient of the scale was stated as 0.91 (De Bruin, 2006; Teleş, 2020).
Change from before implementation, after practice is completed (1th week)
Therapeutic Relationship Evaluation Scale-Nurse Form (TRES-NF)
Time Frame: Change from before implementation, after practice is completed (1th week)
Developed by Coelho et al. (2021) to assess the quality of the therapeutic relationship between psychiatric nurses and psychiatric patients, the Turkish validity and reliability of the scale was established by Duran and Polat (2023). The scale, which consists of a five-point Likert type and 25 items, can be used in one dimension or with four subdimensions as "empathy, self-awareness, participation in care, and orientation". The answers to each item in the scale are specified as "1=Never, 2=Rarely, 3=Sometimes, 4=Frequently, 5=Always". It has been stated that a minimum of 25 and a maximum of 125 points can be obtained if the scale is used in one dimension. It has been stated that if the scale is used in other subdimensions, 5-25 points can be obtained from the empathy subdimension, 6-30 from the self-awareness subdimension, 8-40 from the participation in care subdimension, and 6-30 from the orientation subdimension. As a result of their validity and reliability study, Duran and Polat (
Change from before implementation, after practice is completed (1th week)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

SERDAR TÜRKYILMAZ

Collaborators

Çankırı Karatekin University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Actual)

January 31, 2025

Study Completion (Actual)

February 5, 2025

Study Registration Dates

First Submitted

December 31, 2024

First Submitted That Met QC Criteria

December 31, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 5, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0009-0003-2884-5320

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aromatherapy

Clinical Trials on Aromatherapy Inhalation in Psychiatric Nurses

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe